Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

September 16, 2024--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab ... ADAURA ...

ADAURA Trail Results Reveal 79% Reduction in Risk of Death with Tagrisso The eagerly anticipated data from the Phase III ...

In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration.

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...

AstraZeneca has completed clinical studies to transition Breztri, its inhaled treatment for COPD, to a next-generation ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Nucala gained nods from the FDA to treat ...

FLUMIST ® has been approved in the US as the only self-administered influenza vaccine. FLUMIST, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

AstraZeneca is a company with a turbulent history ... Daiichi apparently declined the offer. Then, in early 2020, more rumours spread that AZ was looking to acquire Gilead, known for its high ...